title: Expression of metallothionein in colorectal cancers and synchronous liver metastases.
abstract: The aim of this study is to clarify whether the expression of metallothionein (MT) is related with the malignant potential in primary colorectal cancer and/or synchronous liver metastasis. Immunohistochemical staining for MT was performed on the specimens of adenocarcinoma of the colon and rectum and its liver metastases in 34 patients treated with curative surgery, respectively. Expression of MT was compared with clinicopathological variables and patient survival. In patients with primary colorectal cancer, positive expression was found in 7 of 34 (20.6%) patients, but MT was not detected in any of the cases of liver metastases (0%; p = 0.0111). In the primary tumor, positive MT expression was significantly associated with a higher degree of lymph node involvement (mean +/- SD: 48.4 +/- 33.8 vs. 18.6 +/- 24.4% in MT-positive and MT-negative tumors, respectively; p = 0.0122). The survival rate in the patients with MT-negative tumors was significantly better than that in those with MT-positive tumors as primary sites (p = 0.0198). MT expression in colorectal cancer may be a potential marker affecting lymph node metastases and may be a predictor of a poor prognosis, particularly in patients with synchronous liver metastases.
authors.affiliation: Department of Histology and Cell Biology, Nagasaki University School of Medicine, Nagasaki, Japan. yhish@net.nagasaki-u.ac.jp
authors.forename: Y
authors.initials: Y
authors.lastname: Hishikawa
authors.forename: H
authors.initials: H
authors.lastname: Kohno
authors.forename: S
authors.initials: S
authors.lastname: Ueda
authors.forename: T
authors.initials: T
authors.lastname: Kimoto
authors.forename: D K
authors.initials: DK
authors.lastname: Dhar
authors.forename: H
authors.initials: H
authors.lastname: Kubota
authors.forename: M
authors.initials: M
authors.lastname: Tachibana
authors.forename: T
authors.initials: T
authors.lastname: Koji
authors.forename: N
authors.initials: N
authors.lastname: Nagasue
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000188:drug therapy / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D015179:Colorectal Neoplasms / Q000737:chemistry* / Q000188:drug therapy / Q000235:genetics / Q000401:mortality / Q000601:surgery; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D015993:Life Tables; D008113:Liver Neoplasms / Q000737:chemistry / Q000188:drug therapy / Q000235:genetics / Q000401:mortality / Q000556:secondary*; D008297:Male; D008668:Metallothionein / Q000032:analysis*; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D015999:Multivariate Analysis; D009363:Neoplasm Proteins / Q000032:analysis*; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D009363:Neoplasm Proteins; D016685:Mitomycin; D004317:Doxorubicin; D008668:Metallothionein; D002945:Cisplatin; D005472:Fluorouracil